Skip to Content
Morningstar

Akebia Therapeutics Inc AKBA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.37 +0.01 (0.74%)
View Full Chart
As of Delayed Price Pre-Open: $1.36 −0.01
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
AKBA is trading at a 29% discount.
Price
$1.36
Fair Value
$2.99
Uncertainty
Very High
1-Star Price
$2.45
5-Star Price
$5.66
Economic Moat
Zdd
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKBA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$1.36
Day Range
$1.35–1.41
52-Week Range
$0.65–2.48
Bid/Ask
$1.35 / $1.36
Market Cap
$286.84 Mil
Volume/Avg
1,628 / 5.1 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
1.32
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
167
Website
https://www.akebia.com

Comparables

Valuation

View More
Metric
AKBA
RYTM
MORF
Price/Earnings (Normalized)
 ———
Price/Book Value
 —14.002.05
Price/Sales
 1.3229.792,339.30
Price/Cash Flow
 ———
Price/Earnings
AKBA
RYTM
MORF

Financial Strength

Metric
AKBA
RYTM
MORF
Quick Ratio
 0.825.2728.43
Current Ratio
 1.185.5828.94
Interest Coverage
 −7.61−13.26—
Quick Ratio
AKBA
RYTM
MORF

Profitability

Metric
AKBA
RYTM
MORF
Return on Assets (Normalized)
 −15.65%−46.12%−19.79%
Return on Equity (Normalized)
 —−76.97%−20.47%
Return on Invested Capital (Normalized)
 −75.91%−76.40%−23.98%
Return on Assets
AKBA
RYTM
MORF
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRMcwppnwfMnwp$557.8 Bil
VRTX
Vertex Pharmaceuticals IncRyfjnzdfFdxtdg$104.7 Bil
REGN
Regeneron Pharmaceuticals IncLcsshxsHffphrw$99.6 Bil
MRNA
Moderna IncLbpcdqtfgSfj$38.8 Bil
ARGX
argenx SE ADRGfnkbjkyNvx$21.4 Bil
BNTX
BioNTech SE ADRClrhmqxcbSqh$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncTlthfbgQvwrxh$18.4 Bil
BMRN
Biomarin Pharmaceutical IncDbcrtlbxGthqrs$17.5 Bil
RPRX
Royalty Pharma PLC Class ACvdbjlhdQytdnq$12.4 Bil
INCY
Incyte CorpHhwcdsqDbjlrpb$11.9 Bil

Sponsor Center